Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Director departure
Appointed director
SELLAS Life Sciences Group, Inc. (SLS) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
08/10/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results"
06/01/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SELLAS Life Sciences Group, Inc. Transcript of Virtual Panel Discussion"
05/11/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results"
03/16/2023 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update"
03/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/01/2023 8-K Quarterly results
02/24/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EXHIBIT 1,1",
"COMMON STOCK PURCHASE WARRANT SELLAS Life Sciences Group, Inc. Warrant Shares: _______ Issue Date: February ___, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. on February __, 2028 but not thereafter, to subscribe for and purchase from SELLAS Life Sciences Group, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the me...",
"SELLAS Life Sciences Group, Inc. 7 Times Square, Suite 2503 New York, New York 10036",
"Printing and Mailing Expenses",
"Investor Contact"
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
02/06/2023 8-K Quarterly results
12/13/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
09/16/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation for September 15, 2022 Webinar",
"SELLAS Life Sciences Group, Inc. Transcript of Investor Webinar"
08/16/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SELLAS Life Sciences Group, Inc. — Business Update and First Quarter 2022 Highlights Call, April 6, 2022 CORPORATE PARTICIPANTS"
04/01/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNDERWRITING AGREEMENT",
"COMMON STOCK PURCHASE WARRANT SELLAS Life Sciences Group, Inc. Warrant Shares: _______ Issue Date: April __, 2022 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. on April [ ], 2027 but not thereafter, to subscribe for and purchase from SELLAS Life Sciences Group, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined herein shall have the meanings...",
"Chrysler Center 666 Third Avenue",
"Printing and Mailing Expenses",
"Investor Contact"
12/16/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update"
09/23/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SELLAS Life Sciences Announces Settlement of Derivative Litigation",
"UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY",
"UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY"
08/12/2021 8-K Quarterly results
Docs: "SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update"
07/07/2021 8-K Quarterly results
06/08/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
06/01/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
01/14/2021 8-K Quarterly results
12/23/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications"
12/14/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Form of Placement Agent Agreement",
"Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C",
"Form of Securities Purchase Agreement, by and among SELLAS Life Sciences Group, Inc. and the Investor",
"SELLAS Announces Pricing of $16.2 Million Registered Direct Offering"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy